Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucinactant in Adults With COVID-19 Associated Acute Lung Injury
NCT04389671Phase 2Completed
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- Jan 2021
- Primary completion
- Feb 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of lucinactant in coronavirus disease 2019 (COVID-19), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), sponsored by Windtree Therapeutics, Inc.. Started Jan 2021; status: completed.
02
Drugs
lucinactant
03
Conditions
coronavirus disease 2019 (COVID-19)acute lung injury (ALI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04389671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04389671.